To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria (clinicaltrials.gov) - Oct 2, 2026 - P3 | N=392 | Completed | Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd | Active, not recruiting ➔ Completed
Trial completion • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
|